Our recent studies showed that schisantherin A (StA) is a promising candidate for PDtreatment, but the pharmacokinetic profile of\nStA is largely unknown. The effects of different formulations on the pharmacokinetics and bioavailability of StA were investigated\nby HPLC equipped with a vacuum degasser, a quaternary pump, a manual sampler, and an ultraviolet detector. The absolute\nbioavailability of StA in nanoemulsion formulation was significantly increased from 4.3% to 47.3%. To the best of our knowledge,\nthis is the first report of absolute bioavailability for StA in rats and successful increase of bioavailability of StA by nanoemulsion\nformulation. The pharmacokinetic profiles of StA could be significantly improved by a safe nanoemulsion formulation. This\nstudy provides a successful example of advanced delivery system for improving the bioavailability of potential central nervous\nsystem (CNS) drug candidate with poor solubility. This novel approach could be an effective alternative solution to overcome\nthe shortcomings of conventional poor drug delivery of CNS drugs. The results of present study not only indicate that StA has\npotential to be developed as a promising oral therapeutic agent for the management of PD but also shed light on novel way to\nimprove bioavailability of PD drugs.
Loading....